Biosimilars Switching Policies in Canada
By EsqSocial Corporation 17/05/21
Further to our post last week on British Columbia’s policy requiring “switching” patients taking Humira, the Alberta government has also implemented a policy, effective May 1, 2021, of requiring that patients over the age of 18 taking Humira switch to one of five adalimumab biosimilars approved by Health Canada: Amgevita, Hadlima, Hulio, Hyrimoz, and Idacio. These patients have until May 1, 2022, to switch to a biosimilar adalimumab; about 3,300 patients are expected to be impacted. According to...
By: Goodwin